Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Prospective, Multicenter Study of Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer

NCT07638631 is registered in ClinicalTrials.gov with Chen Lizhu as lead sponsor.

NCT NCT07638631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07638631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Prospective, Multicenter Study of Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer
Lead sponsor
Chen Lizhu
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 15, 2026
Completion date
June 15, 2030
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastric cancer